- Home
- ORIC vs MLYS Comparison
ORIC vs MLYS Comparison
Compare ORIC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- MLYS
- Stock Information
- Founded
- ORIC 2014
- MLYS 2019
- Country
- ORIC United States
- MLYS United States
- Employees
- ORIC N/A
- MLYS N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- MLYS Health Care
- Exchange
- ORIC Nasdaq
- MLYS Nasdaq
- Market Cap
- ORIC 362.9M
- MLYS 1.0B
- IPO Year
- ORIC 2020
- MLYS 2023
- Fundamental
- Price
- ORIC $10.85
- MLYS $14.63
- Analyst Decision
- ORIC Strong Buy
- MLYS Strong Buy
- Analyst Count
- ORIC 9
- MLYS 4
- Target Price
- ORIC $18.29
- MLYS $27.00
- AVG Volume (30 Days)
- ORIC 932.0K
- MLYS 885.1K
- Earning Date
- ORIC 08-11-2025
- MLYS 08-12-2025
- Dividend Yield
- ORIC N/A
- MLYS N/A
- EPS Growth
- ORIC N/A
- MLYS N/A
- EPS
- ORIC N/A
- MLYS N/A
- Revenue
- ORIC N/A
- MLYS N/A
- Revenue This Year
- ORIC N/A
- MLYS N/A
- Revenue Next Year
- ORIC N/A
- MLYS N/A
- P/E Ratio
- ORIC N/A
- MLYS N/A
- Revenue Growth
- ORIC N/A
- MLYS N/A
- 52 Week Low
- ORIC $3.90
- MLYS $8.24
- 52 Week High
- ORIC $14.67
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- ORIC 61.82
- MLYS 54.08
- Support Level
- ORIC $10.72
- MLYS $14.07
- Resistance Level
- ORIC $11.45
- MLYS $14.70
- Average True Range (ATR)
- ORIC 0.58
- MLYS 0.69
- MACD
- ORIC -0.08
- MLYS 0.15
- Stochastic Oscillator
- ORIC 57.65
- MLYS 80.69
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.